Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04956952 · ClinicalTrials.gov registry record · NA

Enhanced External Counterpulsation in Patients With Fontan Circulation

A NA study of Congenital Heart Disease and Single-ventricle, sponsored by Boston Children's Hospital.

Completed
Registry status
NA
Development phase
23
Enrollment target
1
Study location

NCT04956952 is a NA study of Congenital Heart Disease and Single-ventricle that has completed, run by Boston Children's Hospital. The registered enrollment target is 23 participants, below the 474-participant average among 63 other Congenital Heart Disease trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04956952, a NA study of Congenital Heart Disease and Single-ventricle, has completed, sponsored by Boston Children's Hospital.

COMPLETED
Registry status
NA
Development phase
23 participants
Enrollment target
1
Study location

Study Summary

The purpose of the proposed study is to determine the safety of enhanced external counterpulsation (EECP), a system for compressing the blood vessels in the legs in synchrony with an individual's cardiac rhythm, in clinically well, adult Fontan patients, to document the acute hemodynamic and myocardial effects of EECP on the Fontan circulation, and to demonstrate acute changes in endothelial function after one hour of the procedure.

Interventions

  • DEVICE EECP

Study Locations (1)

Massachusetts

  • Boston Children's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2022-03-31
Est. Completion 2023-05-17
Phase NA

Sponsor

Boston Children's Hospital

462 total trials

What the Registry Record Tells You About NCT04956952

The ClinicalTrials.gov registry entry for NCT04956952 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 474-participant average among 63 other Congenital Heart Disease trials with a reported enrollment target (95% lower). The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Congenital Heart Disease appearing as the primary indexed condition, and to 1 intervention - of which EECP is the first listed.

NCT04956952 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04956952 about?

NCT04956952 is a clinical study titled "Enhanced External Counterpulsation in Patients With Fontan Circulation". The purpose of the proposed study is to determine the safety of enhanced external counterpulsation (EECP), a system for compressing the blood vessels in the legs in synchrony with an individual's cardiac rhythm, in clinically well, adult Fontan patients, to document the acute hemodynamic and myocard...

What is the current status of trial NCT04956952?

This trial is currently completed. It is a NA study. The enrollment target is 23 participants. The study started on 2022-03-31. Estimated completion is 2023-05-17.

What conditions does trial NCT04956952 study?

This clinical trial studies the following conditions: Congenital Heart Disease, Single-ventricle.

What interventions are being tested in trial NCT04956952?

The interventions under investigation include: EECP (DEVICE).

Who is sponsoring clinical trial NCT04956952?

This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04956952 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Congenital Heart Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.